Clinical Trials Directory

Trials / Completed

CompletedNCT02517307

Fatty Acid Oxidation Defects and Insulin Sensitivity

Role of Fatty Acid Oxidation Defects in Insulin Sensitivity

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
41 (actual)
Sponsor
Oregon Health and Science University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty acid oxidation disorders could have an influence on insulin action. Fatty acid oxidation disorders are genetic disorders that inhibit one of the enzymes that converts fat into energy. The investigators will study both normal healthy people and people with a long-chain fatty acid oxidation disorder.

Detailed description

The overall goal of this proposal is to investigate the effects of disordered mitochondrial fatty acid oxidation on insulin resistance in humans. Mitochondrial dysfunction has been implicated in the development of insulin resistance and type 2 diabetes during excess dietary fat intake and from increased release of endogenous free fatty acids , such as occurs in obesity. Controversy exists, however, as to whether this insulin resistance results from intrinsic defects in mitochondrial energy utilization or from abnormalities resulting from excess free fatty acid flux, as well as the role that subsequent accumulation of cellular metabolic intermediates play in impaired insulin signaling. To address these controversies, the investigators will study a unique population of patients with inherited defects in each of the three mitochondrial enzymes in the fatty acid oxidation pathway: 1) very long-chain acyl-CoA dehydrogenase (VLCAD); 2) trifunctional protein (TFP, which includes long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)); and 3) medium-chain acyl-CoA dehydrogenase (MCAD). These proteins are required for the oxidation of sequentially shorter fatty acids . The investigators will test the hypothesis that intrinsic defects in mitochondrial function involving oxidation of long-chain, but not medium-chain, fatty acids are sufficient to prevent intralipid-induced insulin resistance.

Conditions

Interventions

TypeNameDescription
DRUGIntralipid/HeparinCo-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
DRUGGlycerol/SalineCo-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
DRUGHyperinsulinemic euglycemic clampInfusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Timeline

Start date
2016-02-01
Primary completion
2021-01-01
Completion
2021-03-01
First posted
2015-08-07
Last updated
2024-01-30
Results posted
2024-01-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02517307. Inclusion in this directory is not an endorsement.